You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

ERGOLOID MESYLATES - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for ergoloid mesylates and what is the scope of freedom to operate?

Ergoloid mesylates is the generic ingredient in eight branded drugs marketed by Novartis, Mutual Pharm, Sun Pharm Industries, Watson Labs, Sandoz, 3M, Bristol Myers Squibb, Kv Pharm, Lederle, Superpharm, Vangard, and Ivax Pharms, and is included in thirty-four NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for ergoloid mesylates. One supplier is listed for this compound.

Drug Prices for ERGOLOID MESYLATES

See drug prices for ERGOLOID MESYLATES

Recent Clinical Trials for ERGOLOID MESYLATES

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Elizabeth Berry-KravisPhase 2
Sinphar Pharmaceutical Co., LtdPhase 2

See all ERGOLOID MESYLATES clinical trials

Medical Subject Heading (MeSH) Categories for ERGOLOID MESYLATES

US Patents and Regulatory Information for ERGOLOID MESYLATES

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis HYDERGINE ergoloid mesylates TABLET;SUBLINGUAL 009087-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Vangard ERGOLOID MESYLATES ergoloid mesylates TABLET;SUBLINGUAL 088013-001 Sep 20, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Kv Pharm ERGOLOID MESYLATES ergoloid mesylates TABLET;SUBLINGUAL 085899-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Kv Pharm ERGOLOID MESYLATES ergoloid mesylates TABLET;SUBLINGUAL 085900-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Sandoz ALKERGOT ergoloid mesylates TABLET;SUBLINGUAL 087417-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Novartis HYDERGINE ergoloid mesylates TABLET;SUBLINGUAL 009087-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Lederle ERGOLOID MESYLATES ergoloid mesylates TABLET;SUBLINGUAL 086984-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ERGOLOID MESYLATES

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis HYDERGINE LC ergoloid mesylates CAPSULE;ORAL 018706-001 Jan 18, 1983 ⤷  Try a Trial ⤷  Try a Trial
Novartis HYDERGINE ergoloid mesylates SOLUTION;ORAL 018418-001 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.